ENTA250117C5000
- 1.35
- +0.15+12.50%
Enanta Pharmaceuticals Newsroom
Sector Update: Health Care Stocks Mixed Tuesday Afternoon
Top Midday Decliners
CrowdStrike To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Enanta Pharmaceuticals to Appeal Court Ruling on Patent Infringement Case Against Pfizer
Enanta Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Cuts Target Price to $18
Enanta Pharma Analyst Ratings
Promising Virology Outcomes Boost Buy Rating for Enanta Pharmaceuticals Despite Symptom Assessment Concerns
Enanta Pharmaceuticals: Undervalued Potential Beyond Hepatitis C – Buy Recommendation by Roy Buchanan
Evercore Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Cuts Target Price to $20
Oppenheimer Maintains Enanta Pharmaceuticals(ENTA.US) With Hold Rating, Maintains Target Price $14
Enanta Pharmaceuticals (ENTA) Gets a Hold From Oppenheimer
JMP Securities Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $21
Enanta Pharmaceuticals' RSV Platform Advances: Buy Rating Affirmed on Promising Clinical Data
Express News | Enanta Pharmaceuticals Inc - Zelicapavir Well-Tolerated With Favorable Safety Profile
Express News | Enanta Pharmaceuticals Inc - Antiviral Effect Observed With 1.4 Log Viral Load Decline in Part 2
Enanta Pharmaceuticals To Present Topline Results From Its Phase 2 Study Evaluating Zelicapavir For Respiratory Syncytial Virus; Conference Call And Webcast To Discuss Data On Monday, December 9 At 8:30 A.m. ET
Enanta Pharmaceuticals to Present Topline Results From First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported, And Analysts Assigned A US$18.13 Price Target
Enanta Pharmaceuticals (ENTA) Receives a Sell From J.P. Morgan